<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05061758</url>
  </required_header>
  <id_info>
    <org_study_id>AUT-003</org_study_id>
    <nct_id>NCT05061758</nct_id>
  </id_info>
  <brief_title>A Trial of LY3056480 in Patients With SNLH</brief_title>
  <acronym>VESTA</acronym>
  <official_title>A Phase 2 Double Blind, Randomized, Placebo Controlled Trial inVEstigating the Effect and Safety of Several Dosing Regimens of LY3056480 in Patients With STAble Sensorineural Hearing Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Audion Therapeutics BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Audion Therapeutics BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2 trial with LY3056480 in patients with stable SNHL&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      VESTA is a double blinded, randomized, placebo controlled, multi center efficacy phase 2&#xD;
      study comparing three dosing regimens of 250 µg LY3056480. Adult volunteers with stable mild&#xD;
      to moderately-severe SNHL will be recruited through Adult Otolaryngology - Head &amp; Neck&#xD;
      Surgery Services in the US. Four injections of 250µg LY3056480 or placebo administered&#xD;
      trans-tympanically into one ear (worse hearing ear).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2022</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double blinded, randomized, placebo controlled, multi center efficacy phase 2 study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the efficacy of local treatment with LY3056480 in terms of hearing function</measure>
    <time_frame>6 months</time_frame>
    <description>• Number of drug responders with at least a 2dB improvement in an adaptive sentence in noise test (international matrix test) compared to placebo</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Sensorineural Hearing Loss</condition>
  <arm_group>
    <arm_group_label>Four injections of 250µg LY3056480</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatment will be given transtympanically over the course of 2-7 weeks, according to dosing regimens below.&#xD;
Group 1 - Regimen 1. Day 1, Day 4, Day 8, Day 11&#xD;
Group 2 - Regimen 2. Weekly&#xD;
Group 3 - Regimen 3. Every two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Four injections of placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The treatment will be given transtympanically over the course of 2-7 weeks, according to dosing regimens below.&#xD;
Group 1 - Regimen 1. Day 1, Day 4, Day 8, Day 11&#xD;
Group 2 - Regimen 2. Weekly&#xD;
Group 3 - Regimen 3. Every two weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3056480</intervention_name>
    <description>LY3056480 is an inhibitor of gamma-secretase</description>
    <arm_group_label>Four injections of 250µg LY3056480</arm_group_label>
    <arm_group_label>Four injections of placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female between 18 - 65 years of age;&#xD;
&#xD;
          2. Minimum of six months of documented stable hearing loss (+/- 5dB);&#xD;
&#xD;
          3. A documented stable word recognition test (stable for ~ 6 months +/- 6%/3 words)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presenting with a primary complaint of tinnitus&#xD;
&#xD;
          2. Any conductive hearing loss of greater than 15 dB at a single frequency or greater&#xD;
             than 10 dB at two or more contiguous octave frequencies in the study ear&#xD;
&#xD;
          3. History of suspected or diagnosed genetic cause of hearing loss;&#xD;
&#xD;
          4. Partial deafness as defined as hearing loss in any frequency (up to 8 kHz) greater&#xD;
             than 80dB&#xD;
&#xD;
          5. Suspected or known diagnosis of the following inner ear pathology, congenital hearing&#xD;
             loss, fluctuating hearing loss, Ménière's disease, or secondary endolymphatic hydrops,&#xD;
             perilymph fistula, cochlear barotrauma, autoimmune hearing loss, radiation-induced&#xD;
             hearing loss, retro-cochlear lesion, ototoxicity&#xD;
&#xD;
          6. Evidence of acute or chronic otitis media or otitis externa on examination; or a&#xD;
             history of middle ear pathology and/or surgery (except for ear tubes as a child)&#xD;
&#xD;
          7. Any therapy known as ototoxic&#xD;
&#xD;
          8. Participant in a previous trial of LY3056480&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Leonie M Middelink</last_name>
    <phone>+31613328444</phone>
    <email>lmiddelink@audiontherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Allen Micco, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Eye and Ear Infirmary ICAHN school of Medicine Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Maura Cosetti, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eastern Virginia Medical School</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Stephanie Moody, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Hearing Loss, Sensorineural</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

